Early trial yields promising results for NIH's dengue vaccine

01/25/2013 | United Press International

A Phase I trial found the NIH's experimental dengue vaccine TetraVax-DV was safe and triggered strong antibody responses in most of the 112 participants. Four combinations were tested, and one called TV003 activated the most balanced response, according to a report in the Journal of Infectious Diseases. More work is needed, but the results are reason for cautious optimism, said National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA